Concourse Financial Group Securities, Inc. Cel Sci Corp Transaction History

Concourse Financial Group Securities, Inc.

$1.64 Billion
Q3 2024

Number of Shares

Previous 0 NaN%

Holding current value

Previous $0 NaN%

% of portfolio

0.0%

Previous 0.0%

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 10, 2024	BUY	$1.05 - $1.5 $0 - $0	0 New	0 $0
Q2 2024 Jul 23, 2024	BUY	$1.11 - $1.85 $0 - $0	0 New	0 $0
Q1 2024 Apr 30, 2024	BUY	$1.63 - $3.08 $0 - $0	0 New	0 $0
Q4 2023 Feb 07, 2024	SELL	$1.07 - $3.07 $1,556 - $4,466	-1,455 Closed	0 $0
Q3 2021 Nov 09, 2021	BUY	$7.64 - $12.49 $3,132 - $5,120	410 Added 39.23%	1,455 $16,000
Q2 2021 Aug 13, 2021	SELL	$8.68 - $27.49 $7,595 - $24,053	-875 Reduced 45.57%	1,045 $9,000
Q1 2021 May 13, 2021	SELL	$12.0 - $27.64 $9,300 - $21,421	-775 Reduced 28.76%	1,920 $29,000
Q4 2020 Feb 02, 2021	BUY	$11.05 - $16.62 $3,978 - $5,983	360 Added 15.42%	2,695 $31,000
Q3 2020 Nov 13, 2020	BUY	$11.69 - $14.54 $7,014 - $8,724	600 Added 34.58%	2,335 $30,000
Q2 2020 Aug 13, 2020	BUY	$9.75 - $17.6 $2,535 - $4,576	260 Added 17.63%	1,735 $26,000
Q1 2020 May 13, 2020	BUY	$7.54 - $17.05 $4,033 - $9,121	535 Added 56.91%	1,475 $17,000
Q3 2019 Nov 13, 2019	SELL	$6.0 - $9.6 $11,910 - $19,056	-1,985 Reduced 67.86%	940 $8,000
Q2 2019 Aug 13, 2019	BUY	$3.77 - $8.67 $11,027 - $25,359	2,925 New	2,925 $25,000
Q1 2019 May 15, 2019	BUY	$2.58 - $3.54 $0 - $0	0 New	0 $0
Q4 2018 Feb 14, 2019	BUY	$2.65 - $4.26 $0 - $0	0 New	0 $0
Q3 2018 Nov 13, 2018	BUY	$0.83 - $4.16 $0 - $0	0 New	0 $0

Others Institutions Holding CVM

# of Institutions

Shares Held

Call Options Held

27.1K

Put Options Held

150K

View Full List

About CEL SCI CORP

Ticker CVM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,367,500
Market Cap $17.3M
Description
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical ...

More about CVM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Concourse Financial Group Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Concourse Financial Group Securities, Inc. with notifications on news.

Account